Orexo AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORXOY research report →
About the company
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis.
- CEO
- Nikolaj Sørensen
- IPO
- 2018
- Employees
- 74
- HQ
- Uppsala, VIC, SE
Price Chart
- Market Cap
- $70.25M
- P/E
- -3.42
- P/S
- 3.47
- P/B
- 2.34
- EV/EBITDA
- -1.32
- Div Yield
- 0.00%
- Gross Margin
- -75.57%
- Op Margin
- -94.37%
- Net Margin
- -101.06%
- ROE
- -228.39%
- ROIC
- -60.99%
- Revenue
- $25.93M · -95.60%
- Net Income
- $-129,474,393 · 36.22%
- EPS
- $-3.74 · 36.50%
- Op Income
- $-346,029,791
- FCF YoY
- 563.89%
- 52W High
- $4.05
- 52W Low
- $1.48
- 50D MA
- $2.08
- 200D MA
- $2.65
- Beta
- 0.89
- Avg Volume
- 20
Get TickerSpark's AI analysis on ORXOY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ORXOY coverage
Recent articles, reports, and earnings notes.
No research on ORXOY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ORXOY report →Similar companies
Peers in the same neighborhood.